13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • NEO-N BCT

    Acronym: 

    NEO-N BCT

    ACTRN/NCT /ethics: 

    ACTRN12619001308189

    Scientific title: 

    A randomised phase II trial evaluating the efficacy of a nivolumab monotherapy lead in "window" or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancer

    Summary of trial and patient characteristics

    Cancer Type Breast
    Trial Type Treatment
    Phase Phase II Tumour Stream Breast Cancer
    Age Range 18 years and older Cancer Stage Early/In Situ, Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date 2020-03-01
    Molecular Target Anticipated End Date
    Cancer Type Breast
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Breast Cancer
    Cancer Stage Early/In Situ, Locally Recurrent or Locally Advanced
    Anticipated Start Date 2020-03-01
    Anticipated End Date

    Trial Summary

    This study aims to find out how well using Nivolumab on its own before starting standard chemotherapy, or starting treatment with Nivolumab at the same time as standard chemotherapy, helps to reduce tumour size before surgery in patients with previously untreated early stage triple negative breast cancer. Who is it for? You may be eligible for this study if you are 18 years or older and have been diagnosed with triple negative breast cancer that is potentially operable and has not spread to other parts of your body. Tumour block/sections from the initial diagnostic core biopsy must be available.

    Lay Summary

    A randomised phase II trial evaluating the efficacy of a nivolumab monotherapy lead in "window" or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancer

    Sponsor / Cooperative group

    Breast Cancer Trials

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Dr Chris Karapetis Not Yet Recruiting